Bullous pemphigoid is a chronic, relapsing skin disease with underlying type 2 inflammation. It is characterized by intense itching, blisters, skin reddening, and painful lesions. Dupilumab is ...

Oral glucocorticoids alone or combined with other immunosuppressants as treatment for generalized lesions usually have therapeutic effects within days. Localized lesions can be treated with ...

Bullous pemphigoid (BP), which has ... Reaching that endpoint meant that skin lesions had been resolved, with no relapse, and standard treatment with oral corticosteroids had been tailed off ...

Positive results from the pivotal ADEPT phase 2/3 study evaluating the investigational use of Dupixent (dupilumab) in adults with moderate-to-severe bullous pemphigoid (BP) were shared in a ...

“Bullous pemphigoid is a debilitating skin disease ... with this hard-to-treat disease in which the standard of care is oral and topical corticosteroids and immunosuppressants – treatments ...

The measure was defined by complete clinical remission after patients tapered off of standard-of-care oral corticosteroids ... the treatment paradigm for bullous pemphigoid.” ...

The data were shared in a late-breaking oral presentation at the 2025 ... reddening of the skin and painful lesions. “People with bullous pemphigoid live with unrelenting itch, blisters and ...

in adults with moderate-to-severe bullous pemphigoid (BP) were shared in a late-breaking oral presentation at the 2025 American Academy of Dermatology (AAD) Annual Meeting. BP is a chronic ...

in adults with moderate-to-severe bullous pemphigoid (BP) were shared in a late-breaking oral presentation at the 2025 American Academy of Dermatology (AAD) Annual Meeting. BP is a chronic ...